Tarlatamab-dlle is the first t-cell engager that uses the bispecific antibody design for a solid tumor. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tarlatamab-dlle (Imdelltra) to treat patients with...
The CAR T-cell therapy received accelerated approval to treat advanced cases of pretreated follicular lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to lisocabtagene maraleucel (Breyanzi) for the treatment of...
Tisotumab vedotin-tftv is approved to treat certain recurrent or metastatic cervical cancers. The U.S. Food and Drug Administration (FDA) has approved tisotumab vedotin-tftv (Tivdak) for patients with recurrent or metastatic cervical cancer whose disease...
The FDA approved the BRAF inhibitor tovorafenib for pediatric patients with certain Genetic alterations. The U.S. Food and Drug Administration (FDA) has approved tovorafenib (Ojemda) for the treatment of pediatric patients aged 6 months...
The FDA has approved lutetium Lu 177 dotatate for children 12 years or older with some gastroenteropancreatic neuroendocrine tumors. The U.S. Food and Drug Administration (FDA) has approved lutetium Lu 177 dotatate (Lutathera) for...
The FDA has approved nogapendekin alfa inbakicept-pmln, which stimulates immune cells to fight bladder cancer. The U.S. Food and Drug Administration (FDA) has approved nogapendekin alfa inbakicept-pmln (Anktiva) in combination with Bacillus Calmette-Guérin (BCG),...
The FDA has approved the ALK inhibitor alectinib for surgically resectable NSCLC. The U.S. Food and Drug Administration (FDA) has approved alectinib (Alecensa) for use after the surgical removal of a non-small cell lung...
Fam-trastuzumab deruxtecan-nxki was approved for HER2-positive tumors, regardless of the tissue of origin. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu) for adult patients with unresectable...
Mirvetuximab soravtansine-gynx was approved for certain ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA) has approved mirvetuximab soravtansine-gynx (Elaher) for patients with ovarian epithelial, fallopian tube, or peritoneal cancers...
The BCR-ABL inhibitor ponatinib was approved for some patients with acute lymphoblastic leukemia. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to ponatinib (Iclusig) in combination with chemotherapy for adult patients...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More